血友病市场－2026-2031年预测

血友病市场预计将从 2025 年的 122.85 亿美元成长到 2031 年的 178.46 亿美元，复合年增长率为 6.42%。

血友病市场是全球孤儿药和罕见病治疗行业中一个专业且充满活力的细分市场，专注于治疗A型血友病A（VIII因子缺乏症）和B型血友病（IX因子缺乏症）。这些遗传性出血性疾病的特征是某些凝血因子缺乏，导致出血时间延长、关节和肌肉自发性出血，以及危及生命的併发症。该市场已从基本的血浆衍生因子替代疗法发展到包括先进的重组因子浓缩物、半衰期延长产品、非因子疗法和开创性的基因疗法。市场成长的驱动因素包括庞大的患者群体、疾病带来的巨大临床负担，以及旨在改善治疗效果和生活品质的大量创新治疗方法。

主要市场成长要素

血友病的终身慢性特征及其相关的严重併发症是成长要素。若不进行适当治疗，患者将面临反覆关节内出血（血肿）、疼痛性关节病变、慢性疼痛和严重残疾。颅内出血和其他严重出血事件的风险始终存在。这种高发病率使得人们迫切需要有效的预防性和按需治疗方案来预防出血和控制自发性出血，从而支撑了对治疗产品的持续需求。

持续不断的变革性治疗创新正在满足这项临床需求。市场模式经历了数代产品的演变，从标准的重组凝血因子製剂，到减少静脉注射的长效凝血因子浓缩物（EHL），再到非凝血因子疗法，例如可模拟凝血因子VIII功能的双特异性单株抗体emicizumab，该抗体可皮下注射。其中最重要的创新是单剂量基因疗法的出现，旨在可持续地、甚至可能根治性提高体内凝血因子水平。这一不断发展的研发管线正在重新定义治疗模式，并创造巨大的市场价值。

此外，已开发市场健全的监管和报销机制为这些高成本治疗方法的市场进入提供了支持。血友病是一种罕见疾病，拥有完善的治疗指南，这有助于监管机构进行审查，并让支付方认识到该疾病存在巨大的未满足医疗需求。政府政策、专业的血友病治疗中心和患者权益倡导组织共同努力，确保患者能够获得标准疗法和新型疗法，从而创造出有利于新治疗方法引入的环境，即使这些疗法价格昂贵。

主要市场限制因素

市场面临的最大限制因素是治疗费用极为高昂，尤其是基因疗法等新型先进疗法。这些单次治疗的费用可能高达数百万美元，为医疗预算、支付者和健康技术评估机构带来了巨大挑战。这一成本壁垒限制了患者获得治疗的机会，造成了医疗体系之间的不平等，并且需要复杂的按绩效付费合约和支付模式来管理支付方的财务风险。

其他阻碍因素包括可能出现抑制剂（针对因子浓缩物的中和抗体），这会使治疗复杂化并增加成本；以及基因疗法等新兴治疗方法固有的复杂性和风险，包括长期安全性的不确定性和患者反应的个体差异。这些因素造成了临床和经济上的不确定性，并可能减缓其推广应用的速度。

区域展望：北美市场表现强劲

预计北美将继续在全球血友病市场占据主导地位。这一地位归功于该地区完善且覆盖面广的血友病治疗中心网络、较高的诊断和治疗率、优惠的专科药物报销政策，以及众多大型生物製药公司推动创新。该地区的患者和医疗服务提供者通常乐于采用者新治疗方法，且支付体系历来支持高成本。这些因素巩固了北美作为新产品上市和产生收入关键市场的地位。

目录

第一章执行摘要

第二章 市场概览

• 市场概览
• 市场定义
• 调查范围
• 市场区隔

第三章 商业情境

• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析
• 产业价值链分析
• 政策与法规
• 策略建议

第四章 技术展望

第五章 依疾病类型分類的血友病市场

• 介绍
• A型血友病A
• B型血友病
• 其他的

第六章 血友病治疗市场

• 介绍
• 替代疗法
• 基因治疗
• 其他（免疫耐受诱导疗法等）

7. 依产品类型分類的血友病市场

• 介绍
• 重组凝血因子浓缩物
• 血浆衍生凝血因子浓缩物
• 其他药物（例如去氨加压素等）

第八章：血友病市场区域分析

• 介绍
• 北美洲
  • 我们
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他的
• 欧洲
  • 德国
  • 法国
  • 英国
  • 西班牙
  • 其他的
• 中东和非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他的
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 印尼
  • 泰国
  • 其他的

第九章 竞争格局与分析

• 主要企业和策略分析
• 市占率分析
• 合併、收购、协议和合作
• 竞争对手仪錶板

第十章：公司简介

• Bayer AG
• BioMarin Pharmaceutical, Inc.
• CSL Behring
• Novo Nordisk
• Pfizer, Inc.
• Roche（Chugai Pharmaceutical Co.）
• Sanofi（Genzyme Corporation）
• Takeda Pharmaceutical（Shire Plc.）
• Grifols

第十一章附录

• 货币
• 先决条件
• 基准年和预测年时间表
• 相关人员的主要收益
• 调查方法
• 简称

The hemophilia market is expected to grow at a 6.42% CAGR, achieving USD 17.846 billion in 2031 from USD 12.285 billion in 2025.

The hemophilia market is a specialized and dynamic segment within the global orphan drug and rare disease therapeutics industry, focused on the treatment of hemophilia A (factor VIII deficiency) and hemophilia B (factor IX deficiency). This inherited bleeding disorder is characterized by a deficiency in specific clotting factors, leading to prolonged bleeding episodes, spontaneous hemorrhages into joints and muscles, and the risk of life-threatening complications. The market has evolved from basic plasma-derived factor replacement to include advanced recombinant factor concentrates, extended half-life products, non-factor therapies, and pioneering gene therapies. Market growth is driven by the established patient population, the severe clinical burden of the disease, and a robust pipeline of innovative treatments aimed at improving outcomes and quality of life.

Primary Market Growth Drivers

A foundational driver is the lifelong, chronic nature of hemophilia and its severe associated complications. Without adequate treatment, patients face recurrent bleeding into joints (hemarthroses), leading to painful arthropathy, chronic pain, and significant disability. The risk of intracranial and other critical bleeds presents a constant threat. This high morbidity creates an unwavering need for effective prophylactic and on-demand therapies to prevent bleeds and manage breakthrough events, sustaining a consistent demand for treatment products.

This clinical imperative is met by a landscape of continuous and transformative therapeutic innovation. The market has progressed through several generations of products: standard recombinant factors, extended half-life (EHL) factors requiring less frequent intravenous infusion, and non-factor therapies like emicizumab, a bispecific monoclonal antibody that mimics factor VIII function and allows for subcutaneous administration. The most significant innovation is the emergence of one-time gene therapies, which aim to provide a durable, potentially curative elevation of endogenous clotting factor levels. This pipeline evolution is redefining treatment paradigms and creating substantial market value.

Furthermore, strong regulatory and reimbursement pathways in developed markets support market access for these high-cost therapies. Hemophilia is a well-characterized orphan disease with clear treatment guidelines, facilitating regulatory review and payer recognition of the high unmet medical need. Government policies, specialized hemophilia treatment centers, and advocacy groups work to ensure patient access to standard-of-care and novel treatments, creating a supportive environment for the adoption of new therapies despite their premium pricing.

Key Market Restraints

The most significant constraint on the market is the extraordinarily high cost of therapy, particularly for novel advanced treatments like gene therapies. These one-time treatments carry price tags in the multi-million-dollar range, presenting immense challenges for healthcare budgets, payers, and health technology assessment bodies. This cost barrier can limit patient access, create disparities between healthcare systems, and necessitate complex outcomes-based contracting and payment models to manage financial risk for payers.

Additional restraints include the potential for inhibitor development (neutralizing antibodies against factor concentrates), which complicates treatment and increases costs, and the inherent complexity and risk profile of emerging modalities like gene therapy, including long-term safety uncertainties and variability in patient response. These factors introduce clinical and economic uncertainties that can temper the pace of widespread adoption.

Geographical Outlook: North American Market Strength

North America is anticipated to hold a dominant share of the global hemophilia market. This position is attributed to the region's well-established network of comprehensive hemophilia treatment centers, high diagnosis and treatment rates, favorable reimbursement frameworks for specialty pharmaceuticals, and the presence of leading biopharmaceutical companies driving innovation. The region's patients and providers are typically early adopters of novel therapies, and its payer systems have historically supported the high cost of hemophilia care, solidifying its role as the primary market for new product launches and revenue generation.

Competitive Landscape and Therapeutic Segmentation

The competitive landscape includes long-standing plasma product specialists, large biotechnology firms, and emerging gene therapy companies. Competition is intense and revolves around clinical efficacy (annualized bleeding rate reduction), safety profile, dosing convenience (frequency and route of administration), and long-term value proposition.

The market is segmented by therapeutic class:

• Replacement Factors (Standard and EHL): The traditional mainstay, competing on purity, half-life extension, and immuno-tolerance induction.
• Non-Factor Therapies: Representing a paradigm shift with subcutaneous administration and a different mechanism of action.
• Gene Therapies: The new frontier, offering a potential functional cure but with significant upfront cost and long-term data requirements.

Strategic focus for companies involves demonstrating superior real-world outcomes, developing comprehensive patient support services, and navigating the complex market access journey for ultra-orphan drugs.

Future Trajectory and Strategic Considerations

The hemophilia market is at an inflection point, transitioning from chronic replacement to potential durable solutions. The future will be defined by the real-world rollout and long-term follow-up of gene therapies, which will determine their ultimate value and place in the treatment sequence. Competition will intensify between gene therapy for hemophilia A and B and highly effective non-factor prophylactic regimens.

For industry participants, strategic success will depend on generating and communicating robust long-term durability and safety data for gene therapies, developing innovative financing and access models to overcome cost barriers, and tailoring strategies for different global markets with varying healthcare infrastructures. As the standard of care continues to rise, the hemophilia market will remain a high-value, innovation-driven arena where demonstrating transformative patient outcomes is paramount to achieving both clinical and commercial success.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Hemophilia Market Segmentation

• By Disease Type
• Hemophilia A
• Hemophilia B
• Others
• By Therapy
• Replacement Therapy
• Gene Therapy
• Others (Immune Tolerance Induction Therapy etc.)
• By Product Type
• Recombinant Coagulation Factor Concentrates
• Plasma-derived Coagulation Factor Concentrates
• Others (Desmopressin etc.)
• By Geography
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. HEMOPHILIA MARKET BY DISEASE TYPE

• 5.1. Introduction
• 5.2. Hemophilia A
• 5.3. Hemophilia B
• 5.4. Others

6. HEMOPHILIA MARKET BY THERAPY

• 6.1. Introduction
• 6.2. Replacement Therapy
• 6.3. Gene Therapy
• 6.4. Others (Immune Tolerance Induction Therapy etc.)

7. HEMOPHILIA MARKET BY PRODUCT TYPE

• 7.1. Introduction
• 7.2. Recombinant Coagulation Factor Concentrates
• 7.3. Plasma-derived Coagulation Factor Concentrates
• 7.4. Others (Desmopressin etc.)

8. HEMOPHILIA MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Bayer AG
• 10.2. BioMarin Pharmaceutical, Inc.
• 10.3. CSL Behring
• 10.4. Novo Nordisk
• 10.5. Pfizer, Inc.
• 10.6. Roche (Chugai Pharmaceutical Co.)
• 10.7. Sanofi (Genzyme Corporation)
• 10.8. Takeda Pharmaceutical (Shire Plc.)
• 10.9. Grifols

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations